KOSDAQBiotech & Pharma261780

Aribiolab

₩3,410▼ 1.59%2026-10-02 close

Market Cap

₩98.7B

Turnover

₩1.1B

Volume

330,000 shares

Shares out.

29M

PER

—

PBR

7.2×

EPS

-₩536

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Vaccine Platform Meets Group Restructuring

AriBio Lab is a clinical-stage vaccine company built on an immune-enhancing platform, currently navigating group-level restructuring and multiple early-stage pipeline programs while generating almost no revenue.

1
The former ChaVaccine Research Institute changed its name to AriBio Lab on May 29, 2026, taking on the vaccine and immune-platform role within the AriBio group.
2
In 2025, revenue was KRW 158.62 million while the operating loss widened to KRW 14.27 billion and the net loss to KRW 16.04 billion, a sharp expansion from the prior year.
3
Equity shrank from roughly KRW 33.3 billion in 2022 to about KRW 11.9 billion in 2025, while the debt ratio rose from 83% to 151% over the same period.
4
The company holds multiple early-stage assets, including the shingles vaccine candidate CVI-VZV-001, a hepatitis B vaccine, the mRNA immuno-oncology candidate CTRNA-001, and a jointly developed Alzheimer's vaccine program with AriBio.
5
The largest shareholder group, AriBio Holdings and affiliates, raised its combined stake to 20.69% as of August 7, 2026 through third-party share placements.

Business structure

AriBio Lab is an R&D-focused company developing next-generation vaccines and immunotherapies based on its proprietary immune-enhancing platforms, L-pampo and Lipo-pam.

Formerly ChaVaccine Research Institute, the company listed on KOSDAQ in 2021, and after Sorux (now AriBio Holdings) became its largest shareholder in March 2026, it changed its trading name to AriBio Lab effective May 29, 2026.

Under the group's 'ARI ONE' framework, AriBio Holdings functions as a holding entity, AriBio focuses on Alzheimer's drug development centered on the oral candidate AR1001, and AriBio Lab handles the vaccine and immune-platform segment.

Its lead asset is the shingles vaccine candidate CVI-VZV-001, which recently completed second dosing in a domestic Phase 2 trial.

The hepatitis B therapeutic/preventive vaccine CVI-HBV-002 has completed Phase 2b, and the mRNA lipid-nanoparticle-based immuno-oncology candidate CTRNA-001 was selected for a national new drug development program in June 2026 and is under active development.

Separately, the company began co-developing an Alzheimer's vaccine with affiliate AriBio, though this remains at an early candidate discovery and validation stage.

In May 2026, the company signed a memorandum of understanding with Samjin Pharm for domestic commercialization of its shingles and hepatitis B vaccines and joint research on its immune-enhancing platform, securing a commercialization partner. Revenue has remained minimal, consistent with a clinical-stage company without any approved commercial product.

Earnings trend

Quarterly revenue · Operating profit

-₩3.1B25Q2₩0-₩3.4B25Q3₩0-₩5.4B25Q4₩200M-₩1.7B26Q1₩0-₩2.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩200M-₩6.5B2022₩300M-₩6.4B2023₩400M-₩7.7B2024₩200M-₩14.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	—	-₩3.1B	—
2025Q3	₩0	-₩3.4B	—
2025Q4	₩0	-₩5.4B	—
2026Q1	₩200M	-₩1.7B	−985.0%
2026Q2	₩0	-₩2.5B	—

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩200M	-₩6.5B	-₩6.7B	−3604.4%	−20.1%	83.0%
2023	₩300M	-₩6.4B	-₩1.7B	−2182.5%	−4.9%	27.4%
2024	₩400M	-₩7.7B	-₩10.1B	−2076.4%	−36.6%	70.4%
2025	₩200M	-₩14.3B	-₩16B	−8997.2%	−135.3%	151.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Confirmed results show that AriBio Lab's losses have clearly widened in recent periods. Revenue rose modestly from KRW 179.48 million in 2022 to KRW 294.12 million in 2023 and KRW 370.66 million in 2024, before falling back to KRW 158.62 million in 2025.

The operating loss expanded from roughly KRW 6.47 billion in 2022 and KRW 6.42 billion in 2023 to KRW 7.70 billion in 2024 and then sharply to KRW 14.27 billion in 2025.

Net loss attributable to owners narrowed from KRW 6.72 billion in 2022 to KRW 1.75 billion in 2023, then widened again to KRW 10.14 billion in 2024 and KRW 16.04 billion in 2025.

As a result, equity briefly rose from KRW 33.37 billion in 2022 to KRW 35.42 billion in 2023, but then declined rapidly to KRW 27.72 billion in 2024 and KRW 11.86 billion in 2025. The debt ratio fell to 27.4% in 2023 before climbing sharply to 70.4% in 2024 and 151.1% in 2025.

On a quarterly basis, the fourth quarter of 2025 recorded the largest recent operating loss of KRW 5.39 billion and net loss of KRW 5.93 billion, while the first quarter of 2026 narrowed to an operating loss of KRW 1.71 billion and net loss of KRW 2.07 billion, before widening again in the second quarter of 2026 to an operating loss of KRW 2.46 billion and net loss of KRW 2.66 billion.

The trailing four-quarter (2025Q3-2026Q2) net loss attributable to owners totaled KRW 14.42 billion, indicating that double-digit-billion-won annual losses have continued. Operating cash flow has also posted net outflows every year since 2022, showing that core operations have not generated cash internally.

Industry analysis

Korea's pharma and biotech sector is in a phase of expanding technology out-licensing, with domestic firms signing roughly KRW 13 trillion worth of licensing deals in the first half of 2026 alone and expectations building toward an annual figure surpassing KRW 30 trillion.

Group affiliate AriBio has raised industry attention through large deals, including a licensing and commercialization agreement with China's Fosun Pharma worth up to USD 4.7 billion (about KRW 7 trillion) for AR1001, with the full USD 60 million option fee collected, and this visibility spills over into investor awareness of AriBio Lab.

In the vaccine and immune-platform space, however, competition remains intense and led by global big pharma, as seen when a personalized mRNA cancer vaccine developed by Moderna and Merck met its main endpoints in a Phase 3 trial, while Korea also hosts multiple mRNA and vaccine platform companies such as SamyangBiopharm and Genexine.

AriBio Lab's shingles and hepatitis B vaccine candidates remain at Phase 2 and Phase 2b, an earlier stage relative to competitors that have advanced to Phase 3 or approval and commercialization.

The Alzheimer's vaccine field itself has no commercialized product anywhere in the world, with amyloid-beta and tau-targeted vaccine candidates abroad having reached only Phase 2.

The commercialization partnership with Samjin Pharm follows a common pattern in which an early-stage biotech with limited sales infrastructure leverages an established pharmaceutical company's commercial network.

Outlook

Company and group-related disclosures point to two parallel tracks ahead for AriBio Lab: its own pipeline progress and the broader group restructuring.

Following completion of second dosing in the Phase 2 trial of the shingles vaccine CVI-VZV-001, the company has stated it is pursuing follow-up procedures with a goal of securing key clinical results next year.

The mRNA immuno-oncology candidate CTRNA-001 continues candidate optimization work following its selection for a national new drug development program.

The Alzheimer's vaccine program, combined with affiliate AriBio's clinical experience, remains in an early candidate-discovery phase as the company expands its scope of development.

The memorandum of understanding with Samjin Pharm remains at the joint R&D stage, with the specific scope of application and rights to be defined in follow-up agreements.

At the group level, the absorption merger process between AriBio Holdings (formerly Sorux) and AriBio has been reorganized again, with a merger effective date of September 29, 2026 and a listing date for merger shares of October 21, 2026 having been presented.

However, some analysis notes that because AriBio Lab's own largest shareholder changed only recently, at the end of April 2026, regulatory constraints limit any additional merger involving AriBio Lab in the near term.

A group representative has indicated that future strategy could shift depending on the outcome of AriBio's global Phase 3 trial for AR1001, suggesting AriBio Lab's medium-term direction may also be linked to that result.

Valuation

PER

—

PBR

7.2×

ROE

-92.3%

EPS

-₩536

BPS

₩368

Dividend per share

₩0

AriBio Lab has continued to post net losses through the most recent four quarters, making earnings-based valuation metrics difficult to apply.

Price-to-book multiples, whether calculated internally or by KRX, both point to a level where the stock trades at a substantial premium to net asset value, suggesting that group restructuring narratives and pipeline expectations weigh more heavily on market pricing than the accounting net-asset base itself.

As a loss-making company that does not pay dividends, its dividend-related metrics are not comparable to profit-generating peers in the sector. The steady decline in equity from 2022 through 2025 is a relevant reference point for any book-value-based assessment.

The share price has also moved in tandem with recent capital-raising events, including the pricing of the largest shareholder group's participation in share placements.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Large Group-Level Deals Boosting Investor Visibility

Group affiliate AriBio has delivered a string of large-scale achievements, including a licensing and commercialization deal worth up to KRW 7 trillion with China's Fosun Pharma for AR1001 and full collection of a USD 60 million option fee, which has increased market attention toward AriBio-affiliated listed entities as a group.

Capital ties with AriBio Holdings (formerly Sorux) have also strengthened, with the largest shareholder group raising its stake to over 20% through share placements. This intra-group linkage of capital and ownership could affect AriBio Lab's future access to funding.

Diversified Early-Stage Pipeline

With pipeline assets spread across shingles vaccine, hepatitis B vaccine, mRNA immuno-oncology, and a jointly developed Alzheimer's vaccine, risk from the failure of any single candidate is relatively distributed.

CTRNA-001 has been incorporated into a government-supported track after its selection for the national new drug development program. The proprietary L-pampo and Lipo-pam immune-enhancing platforms are applied across multiple pipeline assets, leaving room for platform-level expansion.

Domestic Commercialization Partnership with a Pharma Company

In May 2026, the company signed an MOU with Samjin Pharm for domestic sales of its shingles and hepatitis B vaccines and joint research on its immune-enhancing platform, securing an early commercialization partner.

Access to Samjin Pharm's domestic medical institution sales network is meaningful for an early-stage biotech without its own commercial organization. There is also room for the scope of cooperation to expand into joint platform development through follow-up agreements.

Bear factors

Widening Losses and Eroding Equity Base

The 2025 operating loss reached KRW 14.27 billion and the net loss KRW 16.04 billion, both significantly larger than the prior year, while equity fell from about KRW 35.4 billion in 2023 to about KRW 11.9 billion in 2025. The debt ratio rose to 151.1% in 2025, weakening the financial buffer. Operating cash flow has also posted net outflows every year, sustaining reliance on external financing.

Pipeline Still at an Early Stage with Minimal Revenue

Its core assets, the shingles and hepatitis B vaccine candidates, remain at Phase 2 and Phase 2b respectively, requiring substantial additional time and trials before any commercialization.

The Alzheimer's vaccine program is still at an early candidate-discovery and validation stage, and no Alzheimer's vaccine has been commercialized anywhere in the world. 2025 revenue totaled only KRW 158.62 million, with several quarters recording zero revenue, meaning the company's ability to generate cash from its own operations has not yet been demonstrated.

Complex Group Governance and Related-Party Financing Structure

Governance has shifted rapidly, with the largest shareholder changing from ChaBiotech to Sorux (now AriBio Holdings) and then its combined stake rising sharply again within about four months.

AriBio Lab has been found to have issued convertible bonds to a small investment vehicle with no operating track record while pledging AriBio-related bonds as collateral, prompting market questions about the transparency of financing arrangements among affiliated entities.

Because multiple listed entities within the group (AriBio Holdings and AriBio Lab) have repeated similar financing patterns, the possibility of further share dilution ahead cannot be ruled out.

Risk factors

Financial / Funding

With equity declining for three consecutive years and the debt ratio rising to 151%, operating cash flow has also continued to post net outflows.

This implies a high likelihood of continued reliance on external capital such as share placements or convertible bonds, carrying dilution risk for existing shareholders depending on financing terms.

Clinical / Development

Because all core pipeline assets remain at Phase 2 or earlier, the possibility of clinical failure or delay cannot be ruled out. Pipeline programs targeting unprecedented areas globally, such as an Alzheimer's vaccine, carry particularly high development uncertainty.

Group strategy and capital allocation priorities could also shift depending on the outcome of affiliate AriBio's global Phase 3 trial for AR1001, indirectly affecting AriBio Lab's own development timeline.

Governance / Merger

The largest shareholder has changed repeatedly within recent months, and complex financing arrangements involving convertible bond issuance and collateral provision among affiliated entities have been identified.

As group-level restructuring continues, with the AriBio Holdings-AriBio merger schedule having been revised again, the possibility of future changes to AriBio Lab's own merger or ownership structure cannot be entirely ruled out.

What to watch next

September 29, 2026
The scheduled absorption merger effective date between AriBio Holdings (formerly Sorux) and AriBio; it is worth confirming whether the group's governance and capital restructuring is actually completed on this date.
October 21, 2026
The scheduled listing date for merger shares; it is worth monitoring the resulting new share supply and its impact on affiliated company share prices.
September-October 2026
Affiliate AriBio's top-line data readout for the global Phase 3 POLARIS-AD trial of AR1001 is expected; the outcome could alter investor interest and financing conditions across the group.
Around November 2026
The scheduled disclosure of third-quarter 2026 results; it is worth checking whether the recent trend of widening or narrowing quarterly losses and the equity and debt-ratio trajectory continues.
From the second half of 2026 onward
Whether the MOU with Samjin Pharm evolves into a definitive domestic commercialization agreement, and whether the timeline for securing follow-up shingles vaccine Phase 2 results is maintained, both warrant monitoring.

Overall view

AriBio Lab is a clinical-stage company built on a proprietary immune-enhancing platform, holding multiple early pipeline assets spanning shingles and hepatitis B vaccines, an mRNA immuno-oncology candidate, and a jointly developed Alzheimer's vaccine.

Based on confirmed results, revenue remains extremely minimal, the 2025 operating and net losses widened significantly from the prior year, equity declined markedly over four years, and the debt ratio rose to 151%.

Double-digit-billion-won net losses have continued even on a trailing four-quarter basis, and no clear inflection point toward improved profitability has yet emerged.

At the same time, group-level momentum, including affiliate AriBio's large licensing deals and ongoing Phase 3 trial, along with the domestic commercialization partnership with Samjin Pharm, appears to be translating into broader market attention for AriBio Lab as well.

However, repeated changes in the largest shareholder, an intricate web of convertible-bond and collateral arrangements among affiliated entities, and the still-unfolding group restructuring involving AriBio Holdings and AriBio remain variables that investors need to continue monitoring.

Overall, this stock sits at a juncture where financial structure improvement, clinical progress in its own pipeline, and the direction of group restructuring all need to be watched simultaneously.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.